NPPA Caps Prices of Tenecteplase and 38 Other Drugs
The National Pharmaceutical Pricing Authority (NPPA) has capped the retail prices of 39 essential drugs, including a crucial clot-buster.
Source: GNews India BiotechThe National Pharmaceutical Pricing Authority (NPPA) has recently capped the retail prices of 39 drug formulations. This decision includes the clot-busting drug tenecteplase, manufactured by Boehringer Ingelheim. Tenecteplase is vital for treating acute ischemic stroke and myocardial infarction (heart attack). By capping prices, the NPPA aims to make these essential medicines more affordable and accessible to patients across India. This move is part of the government's ongoing efforts to regulate drug prices and ensure that life-saving medications are not prohibitively expensive. The NPPA regularly reviews and revises drug prices under the Drugs (Prices Control) Order to maintain affordability and availability of scheduled and non-scheduled formulations.
This news is important for competitive exams under Economy and Government Schemes sections. It highlights the role of the NPPA in drug price regulation, a key aspect of public health policy in India. Aspirants should understand the mechanism of drug price control and its impact on healthcare accessibility, relevant for UPSC GS Paper II (Governance) and SSC General Awareness.
- NPPA capped retail prices of 39 drug formulations.
- The clot-buster drug tenecteplase is among the 39 drugs.
- Tenecteplase is manufactured by Boehringer Ingelheim.
- The drug is used to treat acute ischemic stroke and myocardial infarction.
- NPPA operates under the Drugs (Prices Control) Order.
- The decision aims to improve affordability and accessibility of essential medicines.
The NPPA is a government regulatory agency in India. It was established in 1997. Its main function is to fix and revise the prices of controlled bulk drugs and formulations. It also enforces prices and availability of medicines in the country. The NPPA works under the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers.
Tenecteplase is a thrombolytic drug. It is used to dissolve blood clots that can cause heart attacks or strokes. It works by activating plasminogen, which then forms plasmin, an enzyme that breaks down fibrin clots. It is considered a life-saving medication in emergency situations.
The DPCO is an order issued by the Government of India under the Essential Commodities Act, 1955. It empowers the government to control the prices of essential drugs. The latest DPCO was issued in 2013. It lists scheduled drugs whose prices are directly controlled and provides a mechanism for fixing prices of non-scheduled drugs.
Exams often ask about government bodies like NPPA, their establishment year, parent ministry, and key functions. Questions may also focus on the Drugs (Prices Control) Order and its impact on healthcare.
Remember NPPA: 'N' for National, 'P' for Pharmaceutical, 'P' for Pricing, 'A' for Authority. They 'CAP' prices to make drugs 'ACCESSIBLE'.
Frequently Asked Questions
What is the primary role of the National Pharmaceutical Pricing Authority (NPPA)?
The NPPA's primary role is to fix and revise the prices of scheduled bulk drugs and formulations. It also monitors the prices of non-scheduled drugs to ensure they remain within reasonable limits and enforces the availability of medicines in India.
How does the NPPA cap drug prices in India?
The NPPA caps drug prices by calculating a ceiling price for scheduled drugs based on the average price of all brands having more than 1% market share. For non-scheduled drugs, it monitors price increases and can intervene if prices rise above a certain percentage.
What is the significance of capping the price of tenecteplase?
Capping the price of tenecteplase, a critical clot-buster, makes it more affordable for patients suffering from acute ischemic stroke and heart attacks. This improves access to life-saving treatment, especially for economically weaker sections of society.